Double Bond Pharmaceutical AB

Double Bond Pharmaceutical AB is involved in clinical research focused on glioblastoma, with attention to the treatment of newly diagnosed disease in adults and the role of temozolomide-based therapy in the central nervous system.

• Glioblastoma
• Neuro-oncology
• Central nervous system tumours

The sponsor’s research activity is centred on brain cancer care, with clinical interest in therapies intended for intracranial administration and integration with standard of care treatment.